Global Anakinra Market Size, Share and Trends Analysis Report, By Type (10 MIU/ VIAL, 18 MIU/ VIAL, and 25 MIU/VIAL), and By Application (Children and Adults), Forecast (2022-2028)

The global anakinra market is anticipated to grow at a significant CAGR during the forecast period (2022-2028). Anakinra is a class of medicine known as interleukin antagonists. It works by blocking the activity of interleukin that causes inflammation. The global anakinra market is increasing due to the increasing number of arthritis patients across the globe. Obesity is also considered as one of the major factors for the increasing cases of arthritis which in return also driving the growth of the anakinra market. According to Arthritis Foundation, in 2019, one in every three people with the age 18-64 is diagnosed with arthritis. The count for the geriatric population is even worse. More than one in every two men and more than two in every three women are diagnosed with arthritis. In addition, the Arthritis Foundation, for the same time frame stated that, about 54.4 million adults in the US are suffering with some type of arthritis diagnosed by healthcare professionals. Around 22.7% of the total geriatric population in the US are suffering with arthritis. Additionally, the increasing prevalence of rheumatoid arthritis globally is boosting the growth of the anakinra market. According to WHO 2021, an estimation of 14 million people is diagnosed with rheumatoid arthritis globally. According to Rheumatology International 2017, more than 1.36 million adults are diagnosed with rheumatoid arthritis.

For instance, in December 2020, the U.S. Food and Drug Administration (USFDA) approved anakinra to treat deficiency of interleukin (IL1) receptor antagonists to treat DIRA. In September 2021, Swedish Orphan Biovitrum AB and the Hellenic Institute for the Study of Sepsis announced that they have received positive results from the phase 3 SAVE-MORE randomized controlled trail evaluating anakinra plus in hospitalized COVID-19 pneumonia patients. In December 2021, EMA’s Human Medicine Committee has approved the use of anakinra for the treatment of COVID-19 in adult patients with pneumonia requiring supplemental oxygen and who are at a risk if developing severe respiratory failures. Anakinra is also authorized in European Union member states to treat various inflammatory diseases. In April 2018, Swedish Orphan Biovitrum AB announced their approval of anakinra in the European Commission for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still’s Disease in all the 28 European Union member states. In February 2021, Swedish Orphan Biovitrum AB and the Ministry of Health of the Russian Federation has approved anakinra drug for the treatment of Cryopyrin associated periodic syndromes.

Market Coverage
The market number available for – 2022-2028
Base year- 2021
Forecast period- 2022-2028
Segment Covered-
By Type
By Application
Regions Covered-
North America
Europe
Asia-Pacific
Rest of the World

Competitive Landscape- Swedish Orphan Biovitrum AB

Key questions addressed by the report
What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How has COVID-19 impacted the market?
Deviation from the pre-COVID-19 forecast
Most affected region and segment
Who is the leader in the market?
How are players addressing challenges to sustain growth?
Where is the investment opportunity?

Global Anakinra Market Report by Segment
By Type
10 MIU/ VIAL
18 MIU/ VIAL
25 MIU/ VIAL

By Application
Children
Adults